This is a preview of subscription content, log in via an institution to check access.
References
Creasman WT. Estrogen replacement therapy: is previously treated cancer a contraindication?Obstet Gynecol 1991;77:308–312
Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson BL. Estrogen replacement therapy in the patient treated for endometrial cancer.Obstet Gynecol 1986;647:326–330
Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial cancer.Gynecol Oncol 1990;36:189–191
Wren BG. Hormonal therapy following female genital tract cancer.Cancer 1994;4:217–224
Bullock JL, Massey FM, Gambrell RD. Use of medroxyprogesterone acetate to prevent menopausal symptoms.Obstet Gynecol 1975;46:165–168
Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR et al. Megestrol acetate for the prevention of hot flushes.New Engl J Med 1994;331:347–352
Clarke CL, Sutherland RL. ‘Progestin regulation of cellular proliferation.Endocrine Rev 1990;11:266–301
Musgrove EA, Lee CSL, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor, epidermal growth factor receptor, c-fos and c-myc genes.Mol Cell Biol 1991;11:5032–5043
Plu-Bureau G, Le MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease.Br J Cancer 1994;70:270–277
Wren BG. Hormone replacement therapy in women with a history of breast disease. Burger HG, Baillière's clinical endocrinology and metabolism—the menopause. London: Baillière Tindall 1993;7:225–242
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wren, B.G. The management of urogenital atrophy following genital tract cancer. Int Urogynecol J 6, 61–62 (1995). https://doi.org/10.1007/BF01962572
Issue Date:
DOI: https://doi.org/10.1007/BF01962572